The page Thrombolytic Therapy in Stroke has been substantially revised and incorporates the results from the 18 month follow up of patients in the IST3 trial published recently in Lancet Neurology. As is common with tPA stroke trials, much of the relevant data is not easily found (in the study appendix in this case). The results suggest that tPA has no mortality benefit at 18 months (but an increase in early mortality). It causes a modest reduction in disability (NNT 25) at 18 months, but nearly all of this is in patients treated < 3 hours or with moderately severe strokes (NIHSS 16-24). It does not appear to significantly alter patients' quality of life. (Link).